The Magseed® marker, developed by Endomag (London, UK), has recently received European approval for long-term implantation in soft tissues. The tool is intended to mark suspicious lymph nodes as early in treatment as possible so that accurate removal of breast tumors in surgery is more feasible.
Thanks to the rapid improvement of treatment options for those with breast cancer, chemotherapy is now often administered to patients before surgery has been explored. Unfortunately, this can often make it difficult to determine if the cancer has spread beyond the breast, so complete surgical removal of the tumor becomes more uncertain.
The Magseed® marker is a small seed made from surgical grade steel, which is placed in soft tissue to mark tumors before surgery. Once placed, the seed cannot be dislodged or damaged and is detected by the Sentimag® probe (Endomag).
For patients receiving neo-adjuvant chemotherapy, the Magseed® marker will be implanted to mark suspicious lymph nodes before treatment begins. If surgery is then necessary, surgeons could have an accurate idea of which lymph nodes should be removed, allowing a more targeted treatment and accurate staging.
“Ever since we launched the Magseed® marker, we have been asked by European physicians if they can use it to mark a variety of different cancer sites in the body, which also require a longer implantation than the 30 days we had in Europe” commented Eric Mayes, CEO at Endomag. “I’m delighted that we are the first to offer this same level of targeted treatment to European cancer patients.”
The approval of the device was based on data from two independent studies conducted by groups from MD Anderson Cancer Center (TX, USA) and University of California, San Francisco (CA, USA). Both groups demonstrated the ease and accuracy of the Magseed® marker with 100% retrieval success.